To provide consistent and reproducible diagnostic results, we developed an internal quality assurance scheme by performing HER2 FISH on a representative series of BC patients, randomly and prospectively included on TMAs, and by correlating HER2 gene status with IHC scores. The gene discussed is ERBB2; the disease is breast cancer.